Mark has been bringing new medical devices to the market for over 20 years. He has been a co-founder responsible for product development and operations at two drug delivery start-ups that were sold to Hillenbrand Industries and Baxter Healthcare and CEO of Q3DM, a biotech tolls company sold to Beckman-Coulter. He earned his MSME from the Massachusetts Institute of Technology, his BSME from Northeastern University and holds eight utility patents.
Chief Financial Officer
Rich has spent the past 20 years serving public and privately-held companies in the life sciences industry, including Response Biomedical, Kemia, Geneohm Sciences, Cytovia and CoCensys. His expertise includes fundraising, corporate partnerships, and financial planning and analysis. He has overseen finance and operations in multiple companies and has advised many others on finance, strategy, corporate development and operations. Rich began his career as a certified public accountant working with established regional firms in Southern California and earned his B.A. in accounting from San Diego State University.
Pat worked for Hewlett Packard for 25 years, and managed their Environmental Test Department that serviced 6 HP divisions. He was also responsible for creating, managing, and servicing prototypes at their prototype development area. Upon leaving HP, Pat joined Photothera as their Lab Supervisor. Photothera is a medical start-up company that had developed a laser device to treat stroke victims. On a personal note, Pat enjoys flying hot air balloons and has designed and created a wheelchair accessible basket. In addition, for the past 22 years he has traveled to children’s’ special needs summer camps and giving kids rides for free. The organization which Pat belongs to that helps arrange these visits is the only one of its kind in the US.
Wendy is a clinical executive with specialties in pain management and critical care. As a critical care registered nurse, she has served multiple organizations in bedside nursing, nursing leadership, medical education, implementation services, clinical marketing and scientific communications. She has contributed to product development of physiological monitoring devices, infusion pumps, patient safety, and infection prevention tools for medical and technology companies including: CareFusion (Cardinal Health), AACN, HemoTherapies, and VitalCom. She completed her BSN at The Ohio State University and her MHA at Chapman University.
Medipacs’ senior management team, Board of Directors and team of advisors have extensive experience and successful track records introducing novel medical devices and infusion systems that have created meaningful business franchises and established significant value for physicians, patients, employees and shareholders.
Mark McWilliams served as Director of Cell Imaging and Analysis at Beckman Coulter after the recent sale of Q3DM to Beckman in December 2003. Mark was President and Chief Executive Officer and Director of Q3DM, a life-sciences startup that raised several angel and venture capital funding rounds. Previously, Mark was founder and COO of Medication Delivery Devices (MDD), an alternate care infusion systems company that was acquired by Baxter Healthcare in 1996. Mr. McWilliams served as a VP of Research and Development at Baxter Healthcare for three years following the sale of MDD. Prior to MDD, Mark served as Product Development Manager at the founding of Block Medical where he was responsible for bringing the company’s first two FDA approved products rapidly to market. Block was sold to Hillenbrand Industries in 1991. Mark previously worked for Hughes Aircraft, Vacuum General and Martin Marietta. He earned his MSME from the Massachusetts Institute of Technology, his BSME from Northeastern University and holds eight utility patents.
Harry George has over 35 years experience in founding, operating and investing in successful rapid growth technology-related companies. He is a co-founder of Solstice Capital. From 1981 to 1989, Mr. George was co-founder, Director, and Vice-President of Finance for Interleaf Inc. During this time Interleaf grew to be a publicly traded company with $100 million in annual revenue. In January 2000, Interleaf was acquired by Broadvision in a stock merger that valued Interleaf at approximately $900 million. Harry has been a Director of a number of private and public companies and is a member of the Investors’ Circle. Harry is a member of the advisory committee of the MBA program at the Eller School of Business of the University of Arizona He received an AB from Bowdoin College.
Jim Utts is an Operating Partner with Roundtable Healthcare Partners located in Lake Forest, IL (www.roundtablehp.com) having joined the firm in 2007. Prior to this, Jim spent 25 plus years in various senior management roles working for Baxter Healthcare where his most recent position was President of Baxter Europe. He has extensive operating experience in intravenous solutions, drug delivery and infusion therapy businesses worldwide.
Dr. Pinto completed his medical education at St. John’s Medical College in Bangalore, India in 1976. He did a residency in Internal Medicine at Bridgeport Hospital and a Urology Residency at Vanderbilt University Medical Center. He was an Instructor in Urology at Tufts Med School. He has been Chief of Urology at Bridgeport Hospital since January, 2000. His special interests include Benign Prostate Hypertrophy (BPH) and urological oncology. He has presented at numerous regional and national Urology meetings and has published in many journals. He is a member of the American Board of Urology and a member of many urological societies.
In memorium- the Medipacs team was greatly saddened by the passing of Arthur Pinto. We are greatful for his service on the Medipacs Board of Directors.
Mark Banister is the inventor of the Medipacs® pump system and unique polymer actuator materials. He has 5 issued patents and 16 pending patents and has authored several published technical papers on smart polymer materials and devices. Mark has over 30 years of experience in business, product design, polymer chemistry, mechanical engineering, manufacturing and tooling design. Currently the PI on a National Science Foundation STTR Phase II Grant, Mark has been able to leverage over $1M in grant funding into over $3M in angel funding.